Stonepine Capital Management buys $17.8 Million stake in Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA) : Stonepine Capital Management scooped up 149,368 additional shares in Vanda Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 2,068,297 shares of Vanda Pharmaceuticals which is valued at $17.8 Million.Vanda Pharmaceuticals makes up approximately 22.24% of Stonepine Capital Management’s portfolio.

Other Hedge Funds, Including , Cornerstone Capital Management Holdings. boosted its stake in VNDA in the latest quarter, The investment management firm added 47,400 additional shares and now holds a total of 58,400 shares of Vanda Pharmaceuticals which is valued at $502,240.Manufacturers Life Insurance Company The reduced its stake in VNDA by selling 15 shares or 0.05% in the most recent quarter. The Hedge Fund company now holds 28,457 shares of VNDA which is valued at $244,730. Tfs Capital sold out all of its stake in VNDA during the most recent quarter. The investment firm sold 77,342 shares of VNDA which is valued $665,141.Proshare Advisors reduced its stake in VNDA by selling 3,501 shares or 8.64% in the most recent quarter. The Hedge Fund company now holds 37,018 shares of VNDA which is valued at $318,725.

Vanda Pharmaceuticals opened for trading at $8.66 and hit $8.81 on the upside on Monday, eventually ending the session at $8.775, with a gain of 2.03% or 0.175 points. The heightened volatility saw the trading volume jump to 5,61,445 shares. Company has a market cap of $379 M.

On the company’s financial health, Vanda Pharmaceuticals reported $-0.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 4, 2016. Analyst had a consensus of $-0.20. The company had revenue of $33.30 million for the quarter, compared to analysts expectations of $32.57 million. The company’s revenue was up 50.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.10 EPS.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon) Fanapt (iloperidone) Tradipitant (VLY-686) Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Leave a Reply

Vanda Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vanda Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.